Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in
Share
Why It Matters
Kiora bought the right to sell a new eye medicine outside Asia. The deal costs money now and more money if the medicine succeeds.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.